- Home
- SD vs MYGN Comparison
SD vs MYGN Comparison
Compare SD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- MYGN
- Stock Information
- Founded
- SD 2006
- MYGN 1991
- Country
- SD United States
- MYGN United States
- Employees
- SD N/A
- MYGN N/A
- Industry
- SD Oil & Gas Production
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SD Energy
- MYGN Health Care
- Exchange
- SD Nasdaq
- MYGN Nasdaq
- Market Cap
- SD 380.4M
- MYGN 423.1M
- IPO Year
- SD 2007
- MYGN 1995
- Fundamental
- Price
- SD $10.33
- MYGN $4.45
- Analyst Decision
- SD
- MYGN Hold
- Analyst Count
- SD 0
- MYGN 15
- Target Price
- SD N/A
- MYGN $15.14
- AVG Volume (30 Days)
- SD 297.5K
- MYGN 1.2M
- Earning Date
- SD 08-06-2025
- MYGN 08-05-2025
- Dividend Yield
- SD 4.19%
- MYGN N/A
- EPS Growth
- SD 33.83
- MYGN N/A
- EPS
- SD 1.74
- MYGN N/A
- Revenue
- SD $137,611,000.00
- MYGN $831,300,000.00
- Revenue This Year
- SD $37.50
- MYGN N/A
- Revenue Next Year
- SD $5.17
- MYGN $6.68
- P/E Ratio
- SD $6.04
- MYGN N/A
- Revenue Growth
- SD 1.35
- MYGN 7.38
- 52 Week Low
- SD $8.81
- MYGN $3.81
- 52 Week High
- SD $13.93
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- SD 43.69
- MYGN 37.31
- Support Level
- SD $10.08
- MYGN $4.43
- Resistance Level
- SD $10.40
- MYGN $4.83
- Average True Range (ATR)
- SD 0.26
- MYGN 0.28
- MACD
- SD -0.05
- MYGN -0.08
- Stochastic Oscillator
- SD 21.93
- MYGN 1.43
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.